JP6751208B2 - ロチゴチンベヘネート及びその調製方法並びに用途 - Google Patents

ロチゴチンベヘネート及びその調製方法並びに用途 Download PDF

Info

Publication number
JP6751208B2
JP6751208B2 JP2019524492A JP2019524492A JP6751208B2 JP 6751208 B2 JP6751208 B2 JP 6751208B2 JP 2019524492 A JP2019524492 A JP 2019524492A JP 2019524492 A JP2019524492 A JP 2019524492A JP 6751208 B2 JP6751208 B2 JP 6751208B2
Authority
JP
Japan
Prior art keywords
rotigotine
behenate
crystalline form
rotigotine behenate
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019524492A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019523297A (ja
JP2019523297A5 (https=
Inventor
米娜 ▲楊▼
米娜 ▲楊▼
永涛 姜
永涛 姜
▲瑩▼ 孟
▲瑩▼ 孟
涛 王
涛 王
▲銭▼▲銭▼ 徐
▲銭▼▲銭▼ 徐
馨 邵
馨 邵
春▲潔▼ 沙
春▲潔▼ 沙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Luye Pharmaceutical Co Ltd
Original Assignee
Shandong Luye Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Luye Pharmaceutical Co Ltd filed Critical Shandong Luye Pharmaceutical Co Ltd
Publication of JP2019523297A publication Critical patent/JP2019523297A/ja
Publication of JP2019523297A5 publication Critical patent/JP2019523297A5/ja
Application granted granted Critical
Publication of JP6751208B2 publication Critical patent/JP6751208B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C07D333/10Thiophene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
JP2019524492A 2016-07-21 2016-07-21 ロチゴチンベヘネート及びその調製方法並びに用途 Active JP6751208B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/090803 WO2018014277A1 (zh) 2016-07-21 2016-07-21 罗替戈汀山嵛酸酯及其制备方法和用途

Publications (3)

Publication Number Publication Date
JP2019523297A JP2019523297A (ja) 2019-08-22
JP2019523297A5 JP2019523297A5 (https=) 2020-01-23
JP6751208B2 true JP6751208B2 (ja) 2020-09-02

Family

ID=60992805

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019524492A Active JP6751208B2 (ja) 2016-07-21 2016-07-21 ロチゴチンベヘネート及びその調製方法並びに用途

Country Status (15)

Country Link
US (2) US10669249B2 (https=)
EP (1) EP3489227B1 (https=)
JP (1) JP6751208B2 (https=)
KR (1) KR20190031314A (https=)
CN (1) CN109415335B (https=)
AU (1) AU2016415408B2 (https=)
BR (1) BR112019001035A2 (https=)
CA (1) CA3030043C (https=)
ES (1) ES2855976T3 (https=)
MY (1) MY195897A (https=)
PH (1) PH12018550212A1 (https=)
PL (1) PL3489227T3 (https=)
RU (1) RU2717542C9 (https=)
SG (1) SG11201811543XA (https=)
WO (1) WO2018014277A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2717542C9 (ru) * 2016-07-21 2020-08-12 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение
CN108341798B (zh) * 2017-01-23 2021-05-25 沈阳药科大学 罗替戈汀衍生物及其制备和应用
CN114423746A (zh) * 2019-09-30 2022-04-29 山东绿叶制药有限公司 化合物及其制备方法和用途
JP7621009B2 (ja) * 2020-10-27 2025-01-24 ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 テトラヒドロナフタレン系化合物、その医薬組成物及びその使用
WO2024208226A1 (zh) * 2023-04-04 2024-10-10 广州市恒诺康医药科技有限公司 四氢萘类化合物、其药物组合物及其用途
CN119504742B (zh) * 2024-11-18 2025-10-28 陕西师范大学 一种娃儿藤碱和安托芬的全合成方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239196T3 (es) * 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
KR101481643B1 (ko) 2010-11-25 2015-01-12 산동 루예 파마슈티칼 컴파니 리미티드 로티고틴, 이의 유도체 또는 로티고틴 또는 이의 유도체의 약제학적으로 허용가능한 염의 조성물
WO2013168033A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9956201B2 (en) * 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
WO2016014242A1 (en) * 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods
RU2717542C9 (ru) * 2016-07-21 2020-08-12 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение

Also Published As

Publication number Publication date
BR112019001035A2 (pt) 2019-04-30
PL3489227T3 (pl) 2021-05-04
JP2019523297A (ja) 2019-08-22
MY195897A (en) 2023-02-27
US20200255396A1 (en) 2020-08-13
RU2717542C1 (ru) 2020-03-24
PH12018550212A1 (en) 2019-10-28
AU2016415408B2 (en) 2019-04-11
EP3489227B1 (en) 2020-10-21
US10669249B2 (en) 2020-06-02
CN109415335A (zh) 2019-03-01
AU2016415408A1 (en) 2019-01-17
CA3030043C (en) 2021-01-19
SG11201811543XA (en) 2019-02-27
WO2018014277A1 (zh) 2018-01-25
CN109415335B (zh) 2020-06-05
US20190330177A1 (en) 2019-10-31
EP3489227A4 (en) 2020-01-22
ES2855976T3 (es) 2021-09-27
EP3489227A1 (en) 2019-05-29
US11111227B2 (en) 2021-09-07
RU2717542C9 (ru) 2020-08-12
CA3030043A1 (en) 2018-01-25
KR20190031314A (ko) 2019-03-25

Similar Documents

Publication Publication Date Title
JP6751208B2 (ja) ロチゴチンベヘネート及びその調製方法並びに用途
JP2019523297A5 (https=)
JP6691218B2 (ja) 選択的なs1p1受容体アゴニストの新規な結晶形及びその製造方法
JP2019516804A (ja) ナトリウム−グルコース共輸送体阻害薬の新規な結晶形及びその製造方法並びに用途
JP2024088796A (ja) ウチデロン半水和物単結晶、並びにその調製方法及び応用
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
TWI905090B (zh) Mcl-1抑制劑之新結晶型, 其製備方法及包含其之醫藥組合物
CN108473507A (zh) 噻吩并嘧啶化合物的结晶形式
CN104650109A (zh) 紫杉烷类化合物
KR20240158968A (ko) Vanin 효소 억제제의 염 형태, 결정형 및 이의 제조 방법과 용도
WO2018214877A1 (zh) 一种地佐辛晶型及其制备方法
KR102350002B1 (ko) 탁산 화합물, 이들의 제조 방법, 및 이들의 용도
CN107540589A (zh) 一种艾尔骨化醇晶型、药物组合物及制备方法和应用
HK40004499A (en) Rotigotine behenate, and manufacturing method and application thereof
HK40004499B (en) Rotigotine behenate, and manufacturing method and application thereof
JP2022551176A (ja) 置換窒素複素環化合物およびその麻酔作用
RU2844681C2 (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
RU2847971C2 (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
WO2020012245A1 (en) Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
US20170044137A1 (en) Omeprazole sodium semihydrate and preparation method thereof
CN121419965A (zh) 吡啶氮氧化合物的盐型、共晶及其制备方法和应用
EA044230B1 (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
HK40057196A (en) New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191205

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200722

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200813

R150 Certificate of patent or registration of utility model

Ref document number: 6751208

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250